BICX - BioCorRx Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0700
0.0000 (0.00%)
At close: 1:50PM EST
Stock chart is not supported by your current browser
Previous Close0.0700
Open0.0750
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.0680 - 0.0750
52 Week Range0.0410 - 0.2820
Volume108,175
Avg. Volume219,796
Market Cap17.73M
Beta (3Y Monthly)3.75
PE Ratio (TTM)N/A
EPS (TTM)-0.02
Earnings DateNov 14, 2018 - Nov 19, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.13
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Brady Granier, CEO, President, and Director of BioCorRx Inc. Provides Update and Outlook in a New Audio Interview with SmallCapVoice.com

    SmallCapVoice.com, Inc. (SCV) and BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of substance use disorders, announced today that a new audio interview with the Company is now available. Brady Granier called in to SmallCapVoice.com, Inc. to discuss the progress the Company has made in several key areas, the operational outlook for 2019, the launch of a new weight loss program and more. BioCorRx, Inc. issued a third quarter business update in November outlining where the Company stands with NIDA on their grant application process.

  • GlobeNewswire2 months ago

    BioCorRx Inc.’s CEO Talks NIDA Grant Update and a Promising New Product with Uptick Newswire’s Stock Day Podcast

    BioCorRx Inc. (OTCQB: BICX) (the "Company") is a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions. President, CEO, and Director of BioCorRx Inc, Brady Granier talked with Stock Day’s Everett Jolly about exciting developments at the company. Jolly asked for a general explanation of what it is that BioCorRx Inc. does to help fight addiction.

  • GlobeNewswire2 months ago

    BioCorRx Strengthens Intellectual Property Portfolio with Acquisition of Several Patent/Patent Pending Families

    ANAHEIM, CA, Oct. 19, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company’s R&D subsidiary, BioCorRx Pharmaceuticals, has acquired a portfolio of six Therakine Biodelivery GmbH patent families that broadly cover sustained release delivery platforms for the local delivery of biologic and small molecule drugs. The portfolio includes issued patents and several pending patent applications which relate to BICX101, an injectable, sustained release naltrexone for the treatment of opioid and alcohol use disorders.

  • GlobeNewswire2 months ago

    BioCorRx, Inc. Announces Preliminary Agreement with VDM Biochemicals to Develop and Commercialize Patented Opioid Antagonist VDM-001

    ANAHEIM, CA, Oct. 09, 2018 -- VDM-001 represents potential alternative to naloxone for overdose reversal; Potential to reduce cravings from substance use disorder  via.

  • GlobeNewswire2 months ago

    BioCorRx to Exhibit at the International Association of Chiefs of Police 2018 Annual Conference in Orlando, Florida

    ANAHEIM, CA, Oct. 05, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – BioCorRx Inc. (BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that the Company will have an exhibit at the International Association of Chiefs of Police (IACP) 2018 Annual Conference at the Orange County Convention Center in Orlando, Florida on October 6-9th. The IACP Annual Conference and Exposition is the leading law enforcement event, bringing more than 14,000 public safety professionals to learn new techniques and advance their knowledge through 200+ workshops in 12 targeted tracks, live demos, hands-on exhibits, new products and networking opportunities.

  • GlobeNewswire2 months ago

    BioCorRx Provides BICX102 Grant Update

    The National Institute on Drug Abuse has reviewed the grant submission for BICX102 as scheduled. The company received a summary statement shortly after the scientific review which indicated an impact score of 27. Yesterday, the Company received a Just-In-Time (JIT) request from NIDA.

  • GlobeNewswire3 months ago

    BioCorRx CEO Brady Granier Discusses BioCorRx Recovery Program on This Life #YouLive Podcast Hosted by Dr. Drew

    ANAHEIM, CA, Sept. 25, 2018 -- via NEWMEDIAWIRE-- BioCorRx Inc. (OTCQB: BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and.

  • ACCESSWIRE9 months ago

    SeeThruEquity Issues Update on BioCorRx Inc. (OTCQB: BICX) and Increases Price Target to $0.44

    NEW YORK, NY / ACCESSWIRE / March 20, 2018 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued ...